Literature DB >> 17653575

18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.

Marinke Westerterp1, Gerrit W Sloof, Otto S Hoekstra, Fiebo J W Ten Kate, Gerrit A Meijer, Johannes B Reitsma, Ronald Boellaard, J Jan B van Lanschot, Carla F M Molthoff.   

Abstract

PURPOSE: Variable uptake of 18FDG has been noticed in positron emission tomography (PET) studies of patients with oesophageal adenocarcinoma. The aim of the present study was to investigate biological parameters involved in 18FDG uptake in oesophageal adenocarcinoma for selection of patients with increased 18FDG uptake and prediction of prognostic value of 18FDG PET. PATIENTS AND METHODS: Preoperative PET scans were performed in 26 patients with histologically proven oesophageal adenocarcinoma. 18FDG uptake was semiquantitatively measured by SUV(BSAg. )Tumour sections were stained by immunohistochemistry for angiogenic markers (VEGF, CD31), glucose transporter-1 (Glut-1), hexokinase (HK) isoforms, for proliferation marker (Ki67), for macrophage marker (CD68) and for apoptosis marker (cleaved caspase-3). Cell densities, differentiation grade, degree of necrosis and mucus, T-stage and tumour size were assessed. In addition follow-up was analysed.
RESULTS: No association was found between 18FDG uptake and angiogenic markers. In contrast, a significant correlation was found between 18FDG uptake and Glut-1 expression. No correlations were found between 18FDG uptake and HK isoforms, Ki67 or cleaved caspase-3. Also, no correlations were found between 18FDG uptake and cell density, differentiation grade, CD68, mucus and necrosis. However, there was a significant correlation between 18FDG uptake and tumour size and between 18FDG uptake and tumour recurrence.
CONCLUSIONS: Glut-1 expression and tumour size seem parameters associated with 18FDG uptake in patients with biopsy proven oesophageal adenocarcinoma, and may be used to select oesophageal cancer patients in whom 18FDG-PET is of diagnostic value and may predict disease outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653575     DOI: 10.1007/s00432-007-0275-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  58 in total

1.  Carbon-11 choline or FDG-PET for staging of oesophageal cancer?

Authors:  P L Jager; T H Que; W Vaalburg; J Pruim; P Elsinga; J T Plukker
Journal:  Eur J Nucl Med       Date:  2001-10-13

2.  GLUT1 expression in tissue and (18)F-FDG uptake.

Authors:  Norbert Avril
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

3.  Prognostic value of the standardized uptake value in esophageal cancer.

Authors:  Henderik L van Westreenen; John T M Plukker; David C P Cobben; Carolien J M Verhoogt; Henk Groen; Pieter L Jager
Journal:  AJR Am J Roentgenol       Date:  2005-08       Impact factor: 3.959

4.  Over-expression of facilitative glucose transporter genes in human cancer.

Authors:  T Yamamoto; Y Seino; H Fukumoto; G Koh; H Yano; N Inagaki; Y Yamada; K Inoue; T Manabe; H Imura
Journal:  Biochem Biophys Res Commun       Date:  1990-07-16       Impact factor: 3.575

5.  Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?

Authors:  M Schulte; D Brecht-Krauss; B Heymer; A Guhlmann; E Hartwig; M R Sarkar; C G Diederichs; M Schultheiss; J Kotzerke; S N Reske
Journal:  Eur J Nucl Med       Date:  1999-06

6.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors:  N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

7.  The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.

Authors:  V Ahuja; R E Coleman; J Herndon; E F Patz
Journal:  Cancer       Date:  1998-09-01       Impact factor: 6.860

8.  Impact of FDG-PET for staging of oesophageal cancer.

Authors:  Andreas Imdahl; M Hentschel; M Kleimaier; U T Hopt; I Brink
Journal:  Langenbecks Arch Surg       Date:  2004-06-09       Impact factor: 3.445

9.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

10.  Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma.

Authors:  Hiroyuki Kato; Junko Takita; Tatsuya Miyazaki; Masanobu Nakajima; Yasuyuki Fukai; Norihiro Masuda; Minoru Fukuchi; Ryokuhei Manda; Hitoshi Ojima; Katsuhiko Tsukada; Hiroyuki Kuwano; Noboru Oriuchi; Keigo Endo
Journal:  Anticancer Res       Date:  2003 Jul-Aug       Impact factor: 2.480

View more
  20 in total

1.  Accuracy of PET-CT in predicting survival in patients with esophageal cancer.

Authors:  Claire Brown; Ben Howes; Glyn G Jamieson; Dylan Bartholomeusz; Urs Zingg; Thomas R Sullivan; Sarah K Thompson
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

2.  Oesophageal cancer: can imaging improve its assessment?

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

3.  Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Kunihiko Izuishi; Yuka Yamamoto; Takanori Sano; Ryusuke Takebayashi; Yoshihiro Nishiyama; Hirohito Mori; Tsutomu Masaki; Asahiro Morishita; Yasuyuki Suzuki
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

4.  Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.

Authors:  Maria Hentschel; Steffen Appold; Andreas Schreiber; Nasreddin Abolmaali; Andrij Abramyuk; Wolfgang Dörr; Joerg Kotzerke; Michael Baumann; Klaus Zöphel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

5.  Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemoradiotherapy.

Authors:  Itaru Chiba; Kazuhiko Ogawa; Takamitsu Morioka; Hideaki Shimoji; Nao Sunagawa; Shiro Iraha; Tadashi Nishimaki; Naomi Yoshimi; Sadayuki Murayama
Journal:  Oncol Lett       Date:  2010-10-27       Impact factor: 2.967

6.  Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.

Authors:  R S Gillies; M R Middleton; N D Maynard; K M Bradley; F V Gleeson
Journal:  Eur Radiol       Date:  2010-09-04       Impact factor: 5.315

Review 7.  State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment.

Authors:  Jolinta Lin; Seth Kligerman; Rakhi Goel; Payam Sajedi; Mohan Suntharalingam; Michael D Chuong
Journal:  J Gastrointest Oncol       Date:  2015-02

8.  Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma.

Authors:  Suk Hyun Lee; Sangwon Han; Hyo Sang Lee; Sun Young Chae; Jong Jin Lee; Dong Eun Song; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2015-09-22

9.  Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer.

Authors:  Boris Sepesi; Daniel P Raymond; Marek Polomsky; Thomas J Watson; Virginia R Litle; Carolyn E Jones; Rui Hu; Xing Qiu; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2009-10-01       Impact factor: 3.452

10.  Prognostic value of baseline FDG uptake on PET-CT in esophageal carcinoma.

Authors:  Omar S Al-Taan; Amar Eltweri; David Sharpe; Peter M Rodgers; Sukhbir S Ubhi; David J Bowrey
Journal:  World J Gastrointest Oncol       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.